Ex vivo data support the high frequency of myeloid cells in tumors, even when T cells are not present 

Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the targeting precision of antibodies with the power of both the innate and adaptive immune systems, today announced that it will be presenting a poster at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, being held at McCormick Place in Chicago and virtually from June 3-7, 2022. The poster is titled “Characterization of tumor antigen expression and myeloid immune profiles to inform the development of immune-stimulating antibody conjugates (ISACs).”

“The data being presented at ASCO demonstrate that myeloid cells are consistently present in solid tumors. We believe this represents an attractive cellular target to address cancer more broadly. Myeloid cells are key cell types that serve as immunologic sentinels within the tumor microenvironment and can directly kill tumor cells or activate long-lasting cytotoxic T cells,” said Edith A. Perez, M.D., Chief Medical Officer of Bolt Biotherapeutics. “Myeloid-targeted therapies, as single-agents or in combination with approved therapies, have the potential to benefit patients who may or may not have previously benefited from T cell-targeted approaches.”

Bolt Biotherapeutics is currently developing a pipeline of myeloid-targeting therapies, including immune-stimulating antibody conjugates (ISACs) and BDC-3042 (a Dectin-2 agonistic antibody), designed to kill tumors through activation of myeloid cells and subsequent recruitment of T cells. Bolt researchers characterized the myeloid immune landscape of tumor microenvironments from five solid tumor types. The data demonstrate that myeloid cells are present in all tested tumor microenvironments, including those with low T cell infiltration. These findings support the potential for myeloid-directed therapies to activate the innate immune system as a bridge to adaptive immunity, including patient populations who have demonstrated resistance to T cell-mediated immune checkpoint blockade. The data also validate the tumor cell expression of tumor antigens HER2, CEA, and PD-L1, all of which are targets of Boltbody™ ISAC candidates.

The ASCO abstract and poster presentation can be found on the Bolt website under Events & Presentations. Details regarding the presentation are as follows.

Title: Characterization of tumor antigen expression and myeloid immune profiles to inform the development of immune stimulating antibody conjugates (ISACs)
Presented by: Jason Ptacek, Ph.D.
Poster Session: Developmental Therapeutics – Immunotherapy
Time: Sunday, June 5, 8:00 a.m. - 11:00 a.m. CDT
Abstract Number: 2557
Poster Number: 212

About Bolt Biotherapeutics, Inc.
Bolt Biotherapeutics, Inc. is a clinical-stage biotechnology company pioneering a new class of immuno-oncology agents that combine the targeting precision of antibodies with the power of both the innate and adaptive immune systems. Bolt Biotherapeutics’ proprietary Boltbody™ Immune-stimulating Antibody Conjugates (ISACs) are designed to target tumor cells for elimination by the immune system. The Boltbody™ ISAC platform technology harnesses the ability of innate immune agonists to convert cold tumors into immunologically hot tumors, thereby illuminating tumors to the immune system and allowing them to be invaded by tumor-killing cells.

BDC-1001 is a HER2-targeting Boltbody ISAC in an ongoing Phase 1/2 clinical trial enrolling patients with HER2-expressing solid tumors. Bolt is also developing BDC-2034, a Boltbody ISAC targeting CEA, and BDC-3042, an agonist antibody targeting Dectin-2. BDC-3042 is the Company's first myeloid-modulating candidate outside of the Boltbody ISAC platform. In addition, Bolt Biotherapeutics is developing new immuno-oncology Boltbody ISACs through strategic collaborations with leading biopharmaceutical companies. For more information, please visit https://www.boltbio.com/

Forward Looking Statements
This press release contains forward-looking statements about us and our industry that involve substantial risks and uncertainties and are based on our beliefs and assumptions and on information currently available to us. All statements other than statements of historical facts contained in this press release, including statements regarding our clinical trials, and the potential of our myeloid-targeting therapies to benefit patients, are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” or “would,” or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Forward-looking statements represent our current beliefs, estimates and assumptions only as of the date of this press release and information contained in this press release should not be relied upon as representing our estimates as of any subsequent date. These statements, and related risks, uncertainties, factors, and assumptions, include, but are not limited to: the potential product candidates that we develop may not progress through clinical development or receive required regulatory approvals within expected timelines or at all; clinical trials may not confirm any safety, potency or other product characteristics described or assumed in this press release; such product candidates may not be beneficial to patients or become commercialized. These risks are not exhaustive. Except as required by law, we assume no obligation to update these forward-looking statements, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future. Further information on factors that could cause actual results to differ materially from the results anticipated by our forward-looking statements is included in the reports we have filed or will file with the Securities and Exchange Commission, including our Annual Report on Form 10-K for the year ended December 31, 2021 and our Quarterly Reports on Form 10-Q. These filings, when available, are available on the investor relations section of our website at investors.boltbio.com and on the SEC’s website at www.sec.gov.

Media Contacts:
David Schull
Russo Partners, LLC
212-845-4271
This email address is being protected from spambots. You need JavaScript enabled to view it. 

Investor Relations Contact:
Sarah McCabe
Stern Investor Relations, Inc.
212-362-1200
This email address is being protected from spambots. You need JavaScript enabled to view it.